Milan J. Sonneveld, Bettina E. Hansen, Teerha Piratvisuth, Ji‐Dong Jia, Stefan Zeuzem, Edward Gane, Yun‐Fan Liaw, Qing Xie, E. Jenny Heathcote, Henry L.‐Y. Chan, Harry L.A. Janssen – 2 April 2013 – On‐treatment levels of hepatitis B surface antigen (HBsAg) may predict response to peginterferon (PEG‐IFN) therapy in chronic hepatitis B (CHB), but previously proposed prediction rules have shown limited external validity. We analyzed 803 HBeAg‐positive patients treated with PEG‐IFN in three global studies with available HBsAg measurements.

Siegfredo Paloyo, Seigo Nishida, Ji Fan, Akin Tekin, Gennaro Selvaggi, David Levi, Andreas Tzakis – 30 March 2013 – Portal vein thrombosis remains to be a challenging issue during liver transplantation even with the acquisition of innovative surgical techniques and years of experience. Most frequently, an initial eversion thromboendovenectomy is performed and depending on the extent of thrombosis and intraoperative findings, further revascularization options include venous jump grafts, portocaval hemitransposition, renoportal anastomosis or portal vein arterialization.

Lena Sibulesky – 29 March 2013 – Watch a video presentation of this article

Lena Sibulesky – 29 March 2013 – Watch a video presentation of this article

Murli Krishna – 29 March 2013 – Watch a video presentation of this article

Murli Krishna – 29 March 2013 – Watch a video presentation of this article

Lena Sibulesky – 29 March 2013 – Watch a video presentation of this article

Murli Krishna – 29 March 2013 – Watch a video presentation of this article

Murli Krishna – 29 March 2013 – Watch a video presentation of this article

Alexander W. Tarr, Pierre Lafaye, Luke Meredith, Laurence Damier‐Piolle, Richard A. Urbanowicz, Annalisa Meola, Jean‐Luc Jestin, Richard J. P. Brown, Jane A. McKeating, Felix A. Rey, Jonathan K. Ball, Thomas Krey – 28 March 2013 – Severe liver disease caused by chronic hepatitis C virus is the major indication for liver transplantation. Despite recent advances in antiviral therapy, drug toxicity and unwanted side effects render effective treatment in liver‐transplanted patients a challenging task.